Shire Vs Allergan Brings Exclusive Contracts Out Of The Shadows (Again)

Allergan's Medicare Part D contracting tactics for Restasis have blocked Xiidra from the market, Shire lawsuit claims.

Eye

Growing questions over exclusive reimbursement contracts – and whether or not they are fair play when it comes to defending entrenched brands – are poised to be decided in court. The second lawsuit in just over a week charging anti-competitive practices related to exclusive contracting by drug makers was filed Oct. 2 in New Jersey district court by Shire PLC.

Shire alleges that Allergan PLC has coerced payers under Medicare Part D to exclude its new dry eye disease...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet